Introduction
============

Ovarian cancer is a lethal disease that accounts for 5% of cancer deaths in females in the United States and its mortality is second only to breast cancer. In 2017, there were approximately 22,440 new cases and 14,080 deaths from ovarian cancer in the United States[@B1]. At present, preferred management of ovarian cancer is comprehensive staging operation, cytoreductive surgery, and subsequent adjuvant chemotherapy[@B2]. With the development of surgery and targeted drugs, the prognosis of patients with ovarian cancer has been improved significantly, but the 5-year survival rate is still fluctuating at 30%[@B3]. Therefore, identifying favorable prognostic biomarkers for ovarian cancer is urgently needed to develop novel therapeutic strategies and to improve the clinical outcomes of ovarian cancer patients.

Histone deacetylases (HDACs) are a family of enzymes that participate in mediating the dynamic balance of histone acetylation and deacetylation in cells[@B4]. Up to now, 18 subtypes of HDACs have been found in mammalian cells and classified into four classes according to their similarity to the yeast HDAC sequence. Class I HDACs include HDAC1, HDAC2, HDAC3 and HDAC8, which are close to the yeast Rpd3 protein. Class II HDACs consists of HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, which are similar to the yeast Hda1 protein. Class III HDACs, also known as sirtuins, contains SIRT 1-7 because of homologous with yeast transcription factor Sir2 sequence. Interestingly, class IV only has HDAC11[@B5], [@B6]. Among them, Class I, II and IV are Zn^2+^-dependent type, but class III is a Nicotinamide adenine dinucleotide (NAD^+^)-dependent type[@B7].

In recent years, HDACs are considered to play an essential role in cell proliferation, differentiation and apoptosis of several cancers[@B8]-[@B10]. Mottet *et al.* found that HDAC4 was involved in inhibition of p21(WAF1/Cip1) by Sp1/Sp3- rather than p53 binding site. HDAC4 interacted with Sp1 to bind and reduced histone H3 acetylation, indicating that Sp1 plays a key role in HDAC4-mediated p21 inhibition (WAF1/Cip1) [@B8]. A study reported that knockdown of HDAC1 obviously decreased the proliferation of ovarian cancer cells via downregulation of cyclin A expression, and depletion of HDAC3 inhibited the migration of ovarian cancer cell through augmentation of E-cadherin expression[@B10]. Over-expression of HDACs is observed in a variety of human malignancies and is linked to clinicopathological parameters and prognosis[@B11]-[@B13]. For example, HDAC4 was obviously higher in late stages of epithelial ovarian cancer tissues compared with early stages[@B14]. Additionally, enhanced expression of HDAC1 was associated with a shorter disease-specific survival in ovarian cancer patients[@B15]. Up to now, the prognostic significance of each HDACs subtype in ovarian cancer remains unclear. Because the functions of most class III HDACs (SIRT1-7) remain to be elucidated, in the present study, we first entirely investigated the prognostic values of class I, II and IV HDACs members (HDAC1-11) in ovarian cancer patients by Kaplan-Meier plotter database.

Materials and Methods
=====================

The Kaplan-Meier plotter database ([www.kmplot.com](http://www.kmplot.com))[@B16] was used to analyze the correlation between each HDACs mRNA level and prognosis of ovarian cancer patients. In this database, gene expression and clinical data of lung cancer[@B17], ovarian cancer[@B18], gastric cancer[@B19], and breast cancer[@B20] were included. In addition, the clinical data of ovarian cancer patients contained grades, stages, histology and TP53 mutation status. Currently, it has been widely used to analyze the clinical effect of individual genes on overall survival (OS) and progress free survival (PFS) of cancers.

OS of 1656 patients and PFS of 1435 women with ovarian cancer were assessed in Kaplan-Meier plotter database, and the eleven HDACs genes (HDAC1-11) were loaded into the database. Then, patient samples were divided into two groups by median expression (high vs. low expression) and were investigated by a Kaplan-Meier survival plot. The hazard ratio (HR) with 95% confidence intervals (CI) and Log rank *p*-value were calculated automatically on the webpage. If HR and 95% CI were more than 1, the gene was considered as a poor prognostic indicator of ovarian cancer. If 95% CI was less than 1, the gene could be a better prognostic indicator. If 95% CI includes 1, the gene was identified that it had no correlation to the prognosis in ovarian cancer. The relationship between HDACs mRNA level and other clinicopathological parameters including histology subtypes, clinical stages, grades and TP53 mutation was accessed. *P* value of \< 0.05 was considered to be statistically significant.

Result
======

HDACs mRNAs levels are associated with OS and PFS in ovarian cancer patients
----------------------------------------------------------------------------

The prognostic values of each HDACs subtype (HDAC1-11) in ovarian cancer patients were examined in [www.kmplot.com](http://www.kmplot.com). respectively. We found that eight HDACs genes were significantly correlated with outcomes for all ovarian cancer patients. Specifically, high expression of HDAC1, HDAC2, HDAC4, HDAC5 and HDAC11 were correlated to poor OS, *P\<0.05.* (Fig.[1](#F1){ref-type="fig"}A, 1B, 1C, 2A and 2B, HR 95% CI =1.25 (1.1-1.42), 1.28 (1.04-1.59), 1.31 (1.07-1.6), 1.27 (1.03-1.55), and 1.41 (1.14-1.76), respectively). On the contrary, over-expression of HDAC7, HDAC8 and HDAC10 showed a favorable OS, *P\<0.05*. (Fig.[3](#F3){ref-type="fig"}A, 3B and 3C, HR 95% CI =0.85 (0.74-0.98), 0.77 (0.62-0.96) and 0.8 (0.65-0.99), respectively). For PFS, high expression of HDAC1, HDAC2, HDAC4, HDAC5, HDAC7, HDAC8, HDAC10 and HDAC11 were associated with an unfavorable outcome, *P\<0.05*. (Fig.[4](#F4){ref-type="fig"}A, 4B, 4C, 5A, 5B, 6A, 6B and 6C, HR 95% CI =1.27 (1.12-1.44), 1.32 (1.07-1.63), 1.67 (1.38-2.02), 1.37 (1.12-1.68), 1.47 (1.21-1.77), 1.21 (1.06-1.37), 1.27 (1.03-1.57), and 1.32 (1.07-1.63), respectively). From the Fig.[7](#F7){ref-type="fig"} and Fig. [8](#F8){ref-type="fig"}, increased HDAC3, HDAC6 and HDAC9 mRNA expression had no impact on OS and PFS for ovarian cancer patients. (Fig. [7](#F7){ref-type="fig"}A, 7B and 7C, HR 95% CI =0.89 (0.77-1.02), 0.89 (0.78-1.01) and 1.1 (0.95-1.27), Fig. [8](#F8){ref-type="fig"}A, 8B and 8C, HR 95% CI =0.93 (0.82-1.06), 0.93 (0.8-1.07) and 1.1 (0.96-1.26), respectively). Since HDAC1, 2, 4, 5 and 11 had the same OS and PFS prognostic value for ovarian cancer patients, we further studied their prognostic role in different clinicopathological parameters of ovarian cancer patients.

OS and PFS values of HDACs in different ovarian cancer subtypes
---------------------------------------------------------------

The clinical characteristics of ovarian cancer patients in Kaplan-Meier plotter were presented in Table [1](#T1){ref-type="table"}. Next, the OS and PFS values of HDACs in ovarian cancer with different histological subtypes including serous and endometrioid were examined (Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}). For serous ovarian cancer patients, high expression of HDAC1, HDAC2, HDAC4, HDAC5 and HDAC11 was correlated with a poor OS (HR 95% CI =1.25 (1.05-1.5), 1.45 (1.16-1.81), 1.4 (1.11-1.75), 1.29 (1.03-1.61) and 1.46 (1.17-1.83), respectively), and high HDAC2, HDAC4, HDAC5 and HDAC11 expression showed an adverse PFS (1.27(1.04-1.56), 1.51(1.23-1.86), 1.37(1.09-1.71) and 1.53(1.24-1.89), respectively), *P\<0.05*. Nevertheless, among all of them, there was no one gene that had effect on OS and PFS for endometrioid ovarian cancer patients.

Association between the OS and PFS values of HDACs in ovarian cancer and its clinicopathological parameters
-----------------------------------------------------------------------------------------------------------

The relationship between individual HDACs prognostic values and clinical stages (Table [4](#T4){ref-type="table"} and Table [5](#T5){ref-type="table"}), pathological grade (Table [6](#T6){ref-type="table"} and Table [7](#T7){ref-type="table"}) and TP53 mutation (Table [8](#T8){ref-type="table"} and Table [9](#T9){ref-type="table"}) of ovarian cancer patients was further investigated.

Table [4](#T4){ref-type="table"} and Table [5](#T5){ref-type="table"} presented the correlation of HDAC mRNA expression with OS and PFS in different clinical stages of ovarian cancer patients respectively. Increased expression of HDAC2 and HDAC5 was correlated with better OS in stage I+II ovarian cancer patients (HR 95% CI=0.3 (0.11-0.83) and 0.36 (0.13-0.99), respectively), meanwhile, just one gene HDAC1 (HR 95% CI=2.71 (1.02-7.19), *P*=0.0376) was related to poor OS in stage I+II ovarian cancer patients. Moreover, in stage III+IV ovarian cancer patients, we found that HDAC1 (HR 95% CI=1.34 (1.12-1.59), *P*=0.001), HDAC2 (HR 95% CI=1.36 (1.08-1.7), *P*=0.0084) and HDAC11 (HR 95% CI=1.27 (1.01-1.59), *P*=0.0406) mRNA expressions were associated with poor prognosis. For PFS, enhanced HDAC2, HDAC4, HDAC5 and HDAC11 expressions showed an unfavorable PFS (1.24(1.01-1.51), 1.45(1.19-1.76), 1.27(1.03-1.56) and 1.36(1.11-1.66), respectively) for stage III+IV ovarian cancer patients.

With regard to pathological grade, over-expression of HDAC1 (HR 95% CI=1.25 (1.05-1.48), *P*=0.011), HDAC2 (HR 95% CI=1.49 (1.14-1.96), *P*=0.0038), HDAC4 (HR 95% CI=1.39 (1.08-1.79), *P*=0.0092), HDAC5 (HR 95 %CI=1.49 (1.16-1.91), *P* =0.0017) and HDAC11 (HR 95% CI=1.48 (1.15-1.91), *P* =0.0019) showed a poor OS in grade III ovarian cancer patients. In addition, in grade II ovarian cancer patients, HDAC2 (HR 95% CI=1.87 (1.14-3.07), *P*=0.0122) mRNA expression was also correlated to poor OS. About the PFS, HDAC2 (HR 95% CI=1.32 (1.02-1.71)), HDAC4 (HR 95% CI=1.37(1.05-1.77)), HDAC5 (HR 95% CI=1.5(1.14-1.98)) and HDAC11 (HR 95% CI=1.46(1.14-1.89)) mRNA expression were associated with an adverse PFS.

Furthermore, we saw from the Table [8](#T8){ref-type="table"} that the mRNA expression of HDAC2 and HDAC11 (HR 95% CI=1.66 (1.09-2.52) and 1.71 (1.14-2.58), respectively) were correlated to worse OS in mutant-TP53-type ovarian cancer (*P\<*0.05). Among all of them, only HDAC1 (HR 95% CI=0.78 (0.61-0.99), *P*=0.0402) mRNA expression indicated an improved OS in mutant-TP53-type ovarian cancer patients. However, all of HDAC2, HDAC4, HDAC5 and HDAC11 mRNA expressions had a negative PFS value of mutant-TP53-type ovarian cancer patients.

Discussion
==========

In the current study, we comprehensively investigated the prognostic values of eleven HDACs subtype**s** mRNA expressions in ovarian cancer patients using the Kaplan-Meier plotter. We found that mRNAs expressions of HDAC3, HDAC6 and HDAC9 were not associated with the OS and PFS in ovarian cancer patients. Additionally, high mRNAs expressions of HDAC7, HDAC8 and HDAC10 were significantly related to a favorable OS but an unfavorable PFS in ovarian cancer patients. But HDAC1, HDAC2, HDAC4, HDAC5 and HDAC11 mRNA expressions are correlated to poor OS and PFS in ovarian cancer patients. Notably, among of them, HDAC11 also showed an adverse OS and PFS in serous/ stage III+IV/ grade III/ TP53 mutation ovarian cancer patients.

HDAC1 mediated transcription of nucleosome structure changes and participated in cell cycle progression and differentiation, but also promoted cancer gene synthesis, inhibited cell apoptosis and impaired differentiation through mitochondrial translocation[@B21], [@B22]. Numerous studies have reported that HDAC1 is over-expressed in multiple kinds of cancer tissues such as gastric cancer[@B23], breast cancer[@B24], lung cancer[@B25] and ovarian cancer[@B10]. For example, Jin *et al.*[@B26] found that increased expressions of HDCA1 mRNA was detected in 83% of ovarian cancer tissue samples compared to normal tissue samples. Over-expression of HDAC1 protein was detected in 94% of ovarian cancer samples. Moreover, a lot of studies have investigated the correlation between HDAC1 and different cancer patient outcome**s**. However, the results remain controversial. Giaginis *et al*.[@B13] found that HDAC1 expression was positively correlated to longer survival time and was a favorable prognostic factor in pancreatic adenocarcinoma. Mithraprabhu *et al*.[@B12] showed that the multiple myeloma patients with higher expression level of HDAC1 were associated with both shorter progression-free survival and shorter overall survival. Cao *et al.* carried out the meta-analysis to respectively identify that HDAC1 expression was negatively correlated with the overall survival rate of lung cancer patients[@B25] and gastric cancer patients[@B23]. So far, the prognostic values of HDAC1 in ovarian cancer have been still unclear. Weichert *et al*.[@B15] reported that enhanced expression of HDAC1 was associated with a shorter disease-specific survival in ovarian endometrioid carcinomas but not in serous, mucinous, and clear cell carcinomas of the ovary. Besides, Yano *et al.* revealed that overexpression of HDAC1 was detected in the nucleus of ovarian cancer, especially endometrioid ovarian cancer. Moreover, they found that an increased nuclear expression of HDAC1 was showed by comparison between prior to and following chemotherapy. Their data reported that HDAC1 nuclear expression adversely affected overall survival in Serous and endometrioid ovarian cancer[@B27]. Similarly, Hayashi *et al*. demonstrated that HDAC1 over-expression had an unfavorable prognosis value in ovarian cancer[@B10]. Not unexpectedly, our results also observed that increased expression of HDAC1 mRNA was related to poor OS and PFS in ovarian cancer patients. Furthermore, we found that higher expression of HDAC1 was correlated to shorted OS in all of stages, grade III and serous ovarian cancer patients. However, enhanced HDAC1 mRNA expression presented an unfavorable PFS in early stages ovarian cancer patients but a favorable PFS in grade I ovarian cancer patients. Taken together, HDAC1 is a poor OS biomarker for ovarian cancer patients, particularly in poor differentiation and serous ovarian cancer patients.

Most ovarian carcinomas expressed high levels of HDAC2 in the nuclei of tumor cells but not in cytoplasm. HDAC2 protein in serous and mucinous ovarian cancer tissues was significantly higher than those in normal ovarian tissue[@B26]. Weichert *et al*. reported that HDAC2 over-expression was associated with cell proliferation as determined by Ki-67 staining, but has no effect on prognosis of ovarian cancer patients[@B15]. Our results showed that enhanced HDAC2 mRNA expression was linked to unfavorable OS and PFS in ovarian cancer patients, including patients with stages III+IV, TP53-mutanted type, serous and grade III ovarian cancer. But meantime, we also found that increased HDAC2 expression showed better prognosis in stages I+II ovarian cancer patients. Since the number of patients with stages I+II was small, the study need to do in large cases in order to determine the prognostic values of HDAC2 in early stages of ovarian cancer patients.

In many human cancer cells, such as ovarian cancer, pancreatic adenocarcinoma and osteosarcoma, HDAC4 specifically dysregulated cell cycle and led to the development and progression of tumors[@B13], [@B14], [@B28]. In the human glioblastoma model, tumor growth was inhibited *in vitro* by downregulating expression of HDAC4-mediated p21(WAF1/Cip1)[@B10]. The accumulation of HDAC4 induced by fibrillar collagen matrices in the nucleus through co-localization of PP1α, resulted in reduction the expression of p21 and promoted the proliferation and migration of epithelial ovarian cancer cells in turn[@B14]. Besides, HDAC4 expression in epithelial ovarian cancer tissues was obviously higher in late stages of carcinoma than early stages[@B14]. Ahn *et al*.[@B29] found that histone deacetylase inhibitor, apicidin suppressed the growth of transplanted ovarian cancer cells by down-regulating HDAC4 and MMP-2. All these evidences pointed out that HDAC4 was involved in ovarian cancer progression. However, the prognostic role of HDAC4 in ovarian cancer is unknown. According to our results, augmented HDAC4 mRNA expression was correlated to unfavorable outcome in all ovarian cancer patients. Notably, poor PFS was related to late stages, poor differentiation and serous ovarian cancer, while adverse OS was only associated with poor differentiation and serous ovarian cancer.

HDAC5 was reported to lead to the dysregulation of cell proliferation and apoptosis in different cancers[@B30]. Watamoto *et al*. put forward that control of the HDAC5 nucleocytoplasmic distribution might be related to murine erythroleukemia cell differentiation possibly via regulation of GATA-1 transactivation[@B31]. Some data showed that high HDAC5 expression was associated with an poor prognosis for various types of cancer patients including hepatocellular cancer[@B32], breast cancer[@B30] and medulloblastoma[@B33]. Currently, there are no available studies about the prognosis of HDAC5 in ovarian cancer. Our results supported that enhanced HDAC5 expression might indicate worse prognosis of ovarian cancer patients, particularly for poor differentiation and serous patients but better outcome of early stages patients. Besides, HDAC5 mRNA expression was associated with poor PFS for TP53 mutation ovarian cancer patients.

HDAC11, the only member of class IV histone deacetylase, is not only involved in cell division regulation, nervous system development, but also plays an important role in physiological and pathological process of tumor[@B34]-[@B36]. HDAC11 silencing in MYCN-driven neuroblastoma cell lines dramatically induced cell death possibly mediated by apoptotic programs[@B36]. Wang *et al*. reported that a negative correlation between the expression of HDAC11 and p53 in pituitary tumors and HDAC11 interfered with p53 expression in pituitary tumor cells to regulated its apoptosis[@B37]. Feng *et al*. found that HDAC11 might be involved in breast cancer progression[@B38]. But Lucio-Eterovic*et al*. showed that HDAC11 inhibited the development of nervous system tumors[@B39]. Other study revealed that HDAC11 was expressed at a higher level in Hodgkin Reed-Sternberg cells and had a borderline relationship with the OS in classical Hodgkin lymphoma patients[@B40]. To date, no data is related to the prognostic role of HDAC11 in gynecological malignancies. Our result first reported that HDAC11 was a poor prognostic biomarker for ovarian cancer patients, particularly in late stages, poor differentiation, TP53 mutation and serous ovarian cancer patients.

Conclusion
==========

In summary, we revealed that HDAC1, HDAC2, HDAC4 and HDAC5 mRNA expression were related to poor OS and unfavorable PFS in all ovarian cancer patients. Importantly, over-expression HDAC11 mRNA was associated with poor OS and PFS not only in all ovarian cancer patients, but also in serous/ stage III+IV/ grade III/ TP53 mutant ovarian cancer patients. Therefore, HDAC11 may be a potential prognostic biomarker for ovarian cancer patients. However, it is worth noting that we only demonstrated the relationship between the prognosis of ovarian cancer and the expression of HDACs mRNA, but not HDACs protein expression. Therefore, the prognosis values of HDACs protein in ovarian cancer need further exploration.
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###### 

Clinical characteristics of ovarian cancer patients in Kaplan-Meier plotter

  Variable                       Overall Survival (N)   Progress Free Survival (N)
  ------------------------------ ---------------------- ----------------------------
  **Histology**                                         
  All cancer patients            1656                   1435
  Serous cancer patients         1207                   1104
  Endometrioid cancer patients   37                     51
  **Pathological grades**                               
  I                              56                     37
  II                             324                    256
  III                            1015                   837
  **Clinical stages**                                   
  I+II                           135                    163
  III+IV                         1220                   1081
  **TP53 mutation**                                     
  Yes                            506                    483
  No                             94                     84
  **Death event**                930                    978
  **Median survival**            45.23 (m)              20 (m)

N, number of ovarian cancer patients with available clinical data; m, months

###### 

Correlation of HDAC mRNA expression with overall survival in different histology subtypes of ovarian cancer patients.

  HDAC     Histology      cases   HR (95% CI)        *P* value
  -------- -------------- ------- ------------------ -----------
  HDAC1    Endometrioid   37      3.91(0.65-23.55)   0.1085
           Serous         1207    1.25(1.05-1.5)     0.0134\*
  HDAC2    Endometrioid   30      2.2(0.31-15.6)     0.4202
           Serous         523     1.45(1.16-1.81)    0.0011\*
  HDAC4    Endometrioid   30      5.24(0.54-50.47)   0.1091
           Serous         523     1.4(1.11-1.75)     0.0037\*
  HDAC5    Endometrioid   30      0.27(0.03-2.59)    0.2229
           Serous         523     1.29(1.03-1.61)    0.0238\*
  HDAC11   Endometrioid   30      0.23(0.03-1.64)    0.1089
           Serous         523     1.46(1.17-1.83)    0.0008\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with progress free survival in different histology subtypes of ovarian cancer patients.

  HDAC     Histology      cases   HR (95% CI)       P value
  -------- -------------- ------- ----------------- -----------
  HDAC1    Endometrioid   51      0.66(0.25-1.77)   0.4068
           Serous         1104    0.92(0.79-1.07)   0.2908
  HDAC2    Endometrioid   44      1.84(0.64-5.32)   0.2518
           Serous         483     1.27(1.04-1.56)   0.0215\*
  HDAC4    Endometrioid   44      2.25(0.78-6.5)    0.1247
           Serous         483     1.51(1.23-1.86)   9.4e-05\*
  HDAC5    Endometrioid   44      0.49(0.16-1.47)   0.1946
           Serous         483     1.37(1.09-1.71)   0.0063\*
  HDAC11   Endometrioid   44      0.55(0.15-1.97)   0.3496
           Serous         483     1.53(1.24-1.89)   7.1e-5\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with overall survival in different clinical stage ovarian cancer patients.

  HDAC     Clinical stage   cases   HR (95% CI)       *P* value
  -------- ---------------- ------- ----------------- -----------
  HDAC1    I+II             135     2.71(1.02-7.19)   0.0376\*
           III+IV           1220    1.34(1.12-1.59)   0.001\*
  HDAC2    I+II             83      0.3(0.11-0.83)    0.0142\*
           III+IV           487     1.36(1.08-1.7)    0.0084\*
  HDAC4    I+II             83      0.69(0.25-1.92)   0.479
           III+IV           487     1.17(0.93-1.47)   0.1789
  HDAC5    I+II             83      0.36(0.13-0.99)   0.0395\*
           III+IV           487     1.12(0.9-1.41)    0.3114
  HDAC11   I+II             83      3.8(0.86-16.83)   0.059
           III+IV           487     1.27(1.01-1.59)   0.0406\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with progress free survival in different clinical stage ovarian cancer patients.

  HDAC     Clinical stage   cases   HR (95% CI)       *P* value
  -------- ---------------- ------- ----------------- -----------
  HDAC1    I+II             163     2.15(1.22-3.8)    0.0068\*
           III+IV           1081    0.91(0.78-1.05)   0.1959
  HDAC2    I+II             115     0.41(0.16-1.07)   0.0603
           III+IV           494     1.24(1.01-1.51)   0.0374\*
  HDAC4    I+II             115     2.31(0.88-6.06)   0.0803
           III+IV           494     1.45(1.19-1.76)   0.0002\*
  HDAC5    I+II             115     0.43(0.21-0.91)   0.0233\*
           III+IV           494     1.27(1.03-1.56)   0.0238\*
  HDAC11   I+II             115     2.66(0.93-7.63)   0.0585
           III+IV           494     1.36(1.11-1.66)   0.0029\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with overall survival in different pathological grade ovarian cancer patients.

  HDAC     Pathological grade   cases   HR (95% CI)        *P* value
  -------- -------------------- ------- ------------------ -----------
  HDAC1    I                    56      2.24(0.83-6.1)     0.1039
           II                   324     0.9(0.65-1.26)     0.5537
           III                  1015    1.25(1.05-1.48)    0.011\*
  HDAC2    I                    41      0.36(0.11-1.15)    0.0725
           II                   162     1.87(1.14-3.07)    0.0122\*
           III                  392     1.49(1.14-1.96)    0.0038\*
  HDAC4    I                    41      1.6(0.54-4.7)      0.3916
           II                   162     1.52(0.88-2.62)    0.1324
           III                  392     1.39(1.08-1.79)    0.0092\*
  HDAC5    I                    41      3.31(0.92-11.92)   0.0527
           II                   162     0.65(0.41-1.02)    0.0571
           III                  392     1.49(1.16-1.91)    0.0017\*
  HDAC11   I                    41      2.71(0.82-8.96)    0.0901
           II                   162     0.78(0.49-1.25)    0.2961
           III                  392     1.48(1.15-1.91)    0.0019\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with progress free survival in different pathological grade ovarian cancer patients.

  HDAC     Pathological grade   cases   HR (95% CI)       *P* value
  -------- -------------------- ------- ----------------- -----------
  HDAC1    I                    37      0.27(0.09-0.83)   0.014\*
           II                   256     1.18(0.88-1.58)   0.2658
           III                  837     1.11(0.93-1.34)   0.2546
  HDAC2    I                    28      0.33(0.09-1.24)   0.0858
           II                   161     1.31(0.86-1.98)   0.2061
           III                  315     1.32(1.02-1.71)   0.0363\*
  HDAC4    I                    28      2.44(0.65-9.2)    0.173
           II                   161     1.63(1.13-2.36)   0.0086\*
           III                  315     1.37(1.05-1.77)   0.0189\*
  HDAC5    I                    28      0.53(0.14-1.96)   0.3301
           II                   161     1.24(0.85-1.8)    0.2639
           III                  315     1.5(1.14-1.98)    0.0035\*
  HDAC11   I                    28      2.26(0.6-8.46)    0.214
           II                   161     1.25(0.85-1.83)   0.2572
           III                  315     1.46(1.14-1.89)   0.0032\*

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with overall survival in different TP53 mutation status ovarian cancer patients.

  HDAC     TP53 mutation   cases   HR (95% CI)       *P* value
  -------- --------------- ------- ----------------- ---------------
  HDAC1    yes             506     0.78(0.61-0.99)   0.0402\*
           no              94      0.76(0.43-1.35)   0.3472
  HDAC2    yes             124     1.66(1.09-2.52)   0.0172\*
           no              19      Not available     Not available
  HDAC4    yes             124     0.76(0.51-1.14)   0.1866
           no              19      Not available     Not available
  HDAC5    yes             124     1.21(0.8-1.81)    0.3664
           no              19      Not available     Not available
  HDAC11   yes             124     1.71(1.14-2.58)   0.0095\*
           no              19      Not available     Not available

\*: *P*\<0.05

###### 

Correlation of HDAC mRNA expression with progress free survival in different TP53 mutation status ovarian cancer patients.

  HDAC     TP53 mutation   cases   HR (95% CI)       *P* value
  -------- --------------- ------- ----------------- ---------------
  HDAC1    yes             483     0.86(0.68-1.08)   0.1905
           no              84      0.65(0.36-1.15)   0.1316
  HDAC2    yes             124     1.7(1.14-2.54)    0.0087\*
           no              19      Not available     Not available
  HDAC4    yes             124     1.6(1.09-2.36)    0.016\*
           no              19      Not available     Not available
  HDAC5    yes             124     1.59(1.07-2.37)   0.0216\*
           no              19      Not available     Not available
  HDAC11   yes             124     2.16(1.44-3.26)   0.0002\*
           no              19      Not available     Not available

\*: *P*\<0.05

[^1]: Competing Interests: The authors have declared that no competing interest exists.
